Featured Instrumentation

Faricimab-svoa (Vabysmo®) from Genentech is the only FDA-approved dual-pathway therapy for exudative macular degeneration, diabetic macular edema, and retinal vein occlusion. Targeting VEGF and Ang-2, pivotal trial data has shown rapid and sustained efficacy across diseases. The novel combination of targets allows for delivery as a first-line agent with the ability to extend patients out to four months between injections. Genentech is committed to delivering safe and effective tools for vitreoretinal specialists and their patients, and continuing to partner with leaders and students in the field alike to improve patient outcomes.